ESTRO 2024 - Abstract Book

S1608

Clinical - Lung

ESTRO 2024

Sara Linde 1,2 , Hjørdis Hjalting Schmidt 1 , Lone Hoffmann 1,2 , Marie Tvilum 1 , Christina Maria Lutz 1 , Lise Saksø Mortensen 1 , Azza Ahmed Khalil 1,2 , Marianne Marquard Knap 1 , Ditte Sloth Møller 1,2 1 Aarhus University Hospital, Department of Oncology, Aarhus, Denmark. 2 Aarhus University, Department of Clinical Medicine, Aarhus, Denmark

Purpose/Objective:

The standard treatment for patients (pts) with limited disease small cell lung cancer (LD-SCLC) is concurrent chemo radiotherapy, followed by prophylactic cranial irradiation (PCI) for pts with responsive disease. A landmark study of Aupérin et al (PMID: 10441603, 1999) showed a 5% overall survival (OS) benefit for pts treated with PCI. Since then, brain imaging has evolved, and some newer studies indicate that observation could be as effective as PCI, avoiding cognitive side effects from radiation. This study investigated which parameters impacted the referral for PCI and how PCI affected OS.

Material/Methods:

Patient records of 177 consecutive patients with LD-SCLC were retrospectively reviewed. All patients were treated with curative intent at a single institution in Denmark between 2012 and 2020. Pts were treated with 1-4 cycles of platinum/Etoposide concurrent with radiotherapy 45Gy/30fx/10week. PCI dose was 25Gy/10fx/5week. Baseline characteristics is shown in Table 1. The cohort was split in two groups, the ones that received PCI (N: 114 pts) and the ones that did not (N: 63 pts). P values were calculated by Chi 2 test, except for age where an independent samples T-test was used.

Table 1

All

patients

PCI N = 114

No

PCI

Baseline Characteristics

P value

N = 177

N = 63

Gender Male Female

95

(54%)

63

(55%)

32

(51%)

P = 0.60

82 (46%)

51 (45%)

31 (49%)

Age Median [range] in years

P < 0.01

67 [41-83]

66 [41-80]

71 [44-83]

ECOG

PS

PS

0

54

(31%)

42

(37%)

12

(19%)

PS

1

95

(54%)

59

(52%)

36

(57%)

P = 0.04

PS

2

26

(15%)

12

(11%)

14

(22%)

PS 3

2 (1%)

1 (1%)

1 (2%)

Stage IB-IIB IIIA-IIIB IIIC

29

(16%)

14

(12%)

15

(24%)

P = 0.14

109

(62%)

74

(65%)

35

(56%)

39 (22%)

26 (23%)

13 (21%)

Chemotherapy

delivery

P = 0.10